In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on MacroGenics (MGNX). The company’s shares closed yesterday at $15.58.
According to TipRanks.com, Peaker is a 3-star analyst with an average return of 2.5% and a 40.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on MacroGenics is a Moderate Buy with an average price target of $31.33, which is a 101.1% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on MacroGenics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $45.02 million. In comparison, last year the company had a GAAP net loss of $49.54 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2.
